Dublin, Aug. 28, 2024 (GLOBE NEWSWIRE) — The “Meningococcal Vaccines Market Report by Vaccine Type, Composition, Vaccine Serotype, Distribution Channel, End User, and Region 2024-2032” report has been added to ResearchAndMarkets.com’s offering.
The global meningococcal vaccines market size reached US$ 3.6 Billion in 2023. Looking forward, the market is set to reach US$ 7.2 Billion by 2032, exhibiting a growth rate (CAGR) of 8.01% during 2023-2032.
The increasing prevalence of the meningococcal disease among young children and adolescents across the globe represents one of the key factors driving the growth of the market. Furthermore, the rising health consciousness among the masses and the adoption of routine immunization are providing a thrust to the market growth. Meningococcal vaccine aids in preventing the disease and minimizing the long-term effects, such as temporary or permanent deafness, loss of vision and motor skills, seizure and neurological damage.
In line with this, governments of both developed and emerging economies are launching extensive public health programs while emphasizing on the immunization of special risk groups, such as tourists and military personnel, to contain the risks of infections. Additionally, various product innovations, such as the development of ready-to-use liquid formulations that do not require reconstitution, are also contributing to the market growth. Other factors, including extensive research and development (R&D) activities, along with improvements in the healthcare infrastructure, are anticipated to drive the market further.
Key Questions Answered in This Report:
- How has the global meningococcal vaccines market performed so far and how will it perform in the coming years?
- What has been the impact of COVID-19 on the global meningococcal vaccines market?
- What are the key regional markets?
- What is the breakup of the market based on the vaccine type?
- What is the breakup of the market based on the composition?
- What is the breakup of the market based on the vaccine serotype?
- What is the breakup of the market based on the distribution channel?
- What is the breakup of the market based on the end user?
- What are the various stages in the value chain of the industry?
- What are the key driving factors and challenges in the industry?
- What is the structure of the global meningococcal vaccines market and who are the key players?
- What is the degree of competition in the industry?
Key Attributes:
| Report Attribute | Details |
| No. of Pages | 137 |
| Forecast Period | 2023 – 2032 |
| Estimated Market Value (USD) in 2023 | $3.6 Billion |
| Forecasted Market Value (USD) by 2032 | $7.2 Billion |
| Compound Annual Growth Rate | 8.0% |
| Regions Covered | Global |
Competitive Landscape:
- GlaxoSmithKline Plc
- Hualan Biological Engineering Inc.
- Incepta Pharmaceuticals Limited
- Novartis AG
- Pfizer Inc.
- Sanofi S.A.
- Serum Institute of India Ltd.
- Walvax Biotechnology Co. Ltd.
Key Market Segmentation:
Breakup by Vaccine Type:
- Conjugate
- Polysaccharide
- Subcapsular
Breakup by Composition:
- Mono Vaccines
- Combination Vaccines
Breakup by Vaccine Serotype:
- MenACWY
- MenB & Manic
- MenC
- MenA
- MenAC
- Others
Breakup by Distribution Channel:
- Hospital Pharmacies
- Retail Pharmacies
- Institutional Sales
- Others
Breakup by End User:
Breakup by Region:
- North America
- United States
- Canada
- Asia Pacific
- China
- Japan
- India
- South Korea
- Australia
- Indonesia
- Others
- Europe
- Germany
- France
- United Kingdom
- Italy
- Spain
- Russia
- Others
- Latin America
- Brazil
- Mexico
- Others
- Middle East and Africa
For more information about this report visit https://www.researchandmarkets.com/r/ykhe2q
About ResearchAndMarkets.com
ResearchAndMarkets.com is the world’s leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
- Meningococcal Vaccines Market
